Biopharmaceutical
Biotechnology
Cancer Prevention

Geron

$1.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.02 (1.32%) Today
-$0.02 (-1.30%) After Hours

Why Robinhood?

You can buy or sell Geron and other stocks, options, ETFs, and crypto commission-free!

About

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Read More The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Employees
17
Headquarters
Menlo Park, California
Founded
1990
Market Cap
283.34M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
5.00M
High Today
$1.55
Low Today
$1.52
Open Price
$1.52
Volume
623.80K
52 Week High
$6.99
52 Week Low
$0.9547

Collections

Biopharmaceutical
Biotechnology
Cancer Prevention
Pharmaceutical
Health
Medical
Technology

News

Seeking AlphaMay 16

Geron Corporation Imeteslstat Program Update Call Transcript

Geron Corporation. (NASDAQ:GERN) Imeteslstat Program Update Call May 16, 2019 9:00 AM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Andrew Grethlein - Chief Operating Officer Aleksandra Rizo - Chief Medical Officer. Conference Call Participants Chad Messer - Needham & Company Tom Shrader - BTIG George Zavoico - B. Riley FBR Operator Good day, ladies and gentlemen and welcome to Geron’s Imetelstat Program Updat...

1,403
Seeking AlphaMay 16

Geron down 6% on extended timeline for imetelstat in myelofibrosis

Geron (GERN -5.9% ) slips on below-average volume in apparent response to its revised development timeline for imetelstat in myelofibrosis.

1,153
Yahoo FinanceMay 16

Geron Provides Imetelstat Program Update

Conference Call Scheduled for 9:00 a.m. ET today MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good start with the imetelstat IND transfer now complete, enabling us to move forward with the planned opening of the Phase 3 clinical trial in lower risk myelodysplastic syndromes for screening and enrollment, which we continue to expect by mid-year 2019,” said John A. Scarle...

35

Earnings

-$0.05
-$0.04
-$0.04
-$0.03
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 30, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.